Q32 Bio Future Growth
Future criteria checks 0/6
Q32 Bio's earnings are forecast to decline at 31.7% per annum while its annual revenue is expected to grow at 93.9% per year. EPS is expected to decline by 12.1% per annum.
Key information
-31.7%
Earnings growth rate
-12.1%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 93.9% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 08 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -120 | -126 | -111 | 6 |
| 12/31/2025 | N/A | -91 | -87 | -87 | 6 |
| 12/31/2024 | N/A | -53 | N/A | -77 | 6 |
| 9/30/2024 | -15 | -61 | -67 | -67 | N/A |
| 6/30/2024 | -13 | -57 | -32 | -32 | N/A |
| 3/31/2024 | -10 | -46 | -21 | -21 | N/A |
| 12/31/2023 | -7 | -54 | -19 | -19 | N/A |
| 9/30/2023 | 12 | -36 | 2 | 2 | N/A |
| 12/31/2022 | 7 | -43 | -13 | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DB0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DB0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DB0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DB0 is forecast to have no revenue next year.
High Growth Revenue: DB0 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DB0's Return on Equity is forecast to be high in 3 years time